The third "A-H" company in the field of domestic CRO is about to be born.

Pharmaceutical Network Corporate News: Following the drug Mingkang, Kang long into, clinical CRO leader Tiger Pharmaceutical son has also been proposed to go to Hong Kong listing.2012, Tyger Pharma was listed on the Shenzhen Stock Exchange.the selection of Hong Kong stocks listed, Tyger Pharma will become the third domestic CRO field "A-H" company.data shows that Tiger Pharma is a contract research organization (CRO) that specializes in providing clinical trial professional services for the development of new drugs.'s core business is to focus on clinical research in innovative drug research and development, from preclinical services to clinical I, II, III and IV phases.is understood that since the listing of Tyger Pharmaceuticals, its performance in the A-share market is very good.early 2019, The price of Tyger Pharma is low at 36 yuan per share, into July this year, the overall upward trend.so far, the company's share price is 103.80 yuan, with a market value of 77.8 billion yuan. The stock has risen more than 60 per cent since the start of the.Tager Pharmaceuticals announced that the company will issue about 107 million shares from July 28 to July 31, including a public offering of 588.86 million shares, an international offering of about 101 million shares, an issue price of 88-100 Hong Kong dollars per share, 100 shares per lot, is expected to be completed on July 31, the company will be listed on August 7.it is understood that the funds raised by the TAG Pharma IPO in Hong Kong are mainly used to enhance operating capacity to meet the increasing demand in overseas markets, to fund future potential acquisitions or investments, to supplement existing businesses.in the industry's view, the Currenter Pharma in the A-share basis to choose to add code H shares, on the one hand, is conducive to increasing financing channels, on the other hand, CRO business also needs to move towards the international route of development, Hong Kong stock listing helps it to get more overseas investment institutions, large pharmaceutical enterprises of all ages.Tag Pharma is the leading domestic clinical contract research institution, public information shows that by the end of 2018, Tyger Pharma participated in nearly 160 innovative drug projects in clinical trials, involving infectious diseases, tumors, endocrinology and cardiovascular fields.also data show that in 2017-2019, the company completed more than 400 clinical research and development outsourcing projects., Tag Pharma has 17 overseas locations in 12 countries and regions in Asia Pacific, North America and Europe, with 732 overseas team members to meet the growing overseas needs of Chinese customers overseas, as well as the growing cross-regional project research and development needs of Chinese and international bidder customers., the growth rate of Tag Pharma's revenue has slowed in recent years.financial data show that in 2017-2019, Tyger Pharmaceuticals' revenue increased from 1.683 billion yuan to 2,803 million yuan, although 21.91 percent year-on-year in 2019 and 36.67 percent year-on-year in 2018.entered the first quarter of 2020, affected by the special period, Tyger Pharma achieved revenue of 650 million, up 6.77 percent year-on-year, the growth rate slowed.and research and development investment, the research and development costs of Tyger Pharmaceuticals in 2017-2019 and the first quarter of 2020 were 49.7 million yuan, 88 million yuan, 124 million yuan and 34.23 million yuan, respectively.Based on 2019 revenue and the number of clinical trials under way as of the end of 2019, Tiger Pharma is China's largest clinical contract research institution, and in 2019 the company ranks among the top 10 clinical contract research institutions worldwide.in addition, the two internationally renowned VC Gaoyu Capital and Temasek both hold shares in Tyger Pharmaceuticals, and there is a strong trend to increase their holdings.it is understood that as of the first quarter of 2020, Gaoyu Capital holds 7.5 million shares in Tag Pharmaceuticals, accounting for 1% of the total share capital, and the market value of Gao's position reached 841 million yuan as of July 22.other shareholders, Temasek owns 2.64 per cent..